Effects of disease modifying treatments on cognitive dysfunction in multiple sclerosis

Neurological Sciences

Volumn 31, Issue SUPPL. 2, 2010, Pages

  Comi, Giancarlo ^a  

^a NONE

Author keywords

Cognitive impairment; Disease modifying treatments; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; NATALIZUMAB; PLACEBO;

ARTICLE; COGNITIVE DEFECT; DRUG EFFICACY; DRUG SAFETY; GRAY MATTER; HUMAN; IMMUNOMODULATION; MILD COGNITIVE IMPAIRMENT; MULTIPLE SCLEROSIS; PATHOGENESIS; POSTMARKETING SURVEILLANCE; QUALITY OF LIFE; TREATMENT RESPONSE; WHITE MATTER;

COGNITION DISORDERS; HUMANS; IMMUNOMODULATION; MULTIPLE SCLEROSIS;

EID: 78650518920     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-010-0436-9     Document Type: Article

References (25)

1. G Comi M Filippi V Martinelli, et al. 1996 Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis J Neurol Sci 132 222 227 10.1016/0022-510X(95)00168-2
2. MP Amato V Zipoli E Portaccio 2006 Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies J Neurol Sci 245 41 46 10.1016/j.jns.2005.08.019 16643953 (Pubitemid 43775956)
3. SP Ryan 1996 Competence and the elderly patient with cognitive impairments Aust N Z J Psychiatry 30 768 773 1:STN:280:DyaK2s7oslSisw%3D%3D 10.3109/00048679609065043 9034465
4. Marra C, Ferraccioli M, Vita MG et al. (2010) Patterns of cognitive decline and rates of conversion to dementia in patients with degenerative and vascular forms of MCI. Curr Alzheimer Res [Epub ahead of print]
5. SM Rao GJ Leo L Bernardin, et al. 1991 Cognitive dysfunction in multiple sclerosis I. Frequency, patterns, and prediction Neurology 41 685 691 1:STN:280:DyaK3M3is1Kltw%3D%3D 2027484
6. P Hamalainen J Ruutiaine 1998 Cognitive decline in multiple sclerosis Int Msj 6 51 57
7. MP Amato G Ponziani F Rossi, et al. 2001 Quality of life in multiple sclerosis: the impact of depression, fatigue and disability Mult Scler 7 340 344 1:STN:280:DC%2BD3MnnvVGmsw%3D%3D 11724451
8. G Comi B Colombo V Martinelli 2000 Prognosis-modifying therapy in multiple sclerosis Neurol Sci 21 S893 S896 1:STN:280:DC%2BD3M3gt1OntA%3D%3D 10.1007/s100720070033 11205370
9. RA Rudick 1999 Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics Arch Neurol 56 1079 1084 1:STN:280:DyaK1Mvhs12isw%3D%3D 10.1001/archneur.56.9.1079 10488808 (Pubitemid 29426794)
10. LD Jacobs DL Cookfair RA Rudick, et al. 1996 Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol 39 284 294 10.1002/ana.410390304 (Pubitemid 26100751)
11. J Fischer RL Priore LD Jacobs, et al. 2000 Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis Ann Neurol 48 885 892 1:CAS:528:DC%2BD3MXhtlKqsg%3D%3D 10.1002/1531-8249(200012)48:6<885::AID- ANA9>3.0.CO;2-1 11117545
12. JA Cohen GR Cuttere JS Fischer, et al. 2002 Benefit of interferon β-1a on MSFC progression in secondary progressive MS Neurology 59 679 687 1:CAS:528:DC%2BD38XnvVSntr8%3D 12221157
13. NH Pliskin PD Hamer DS Goldstein, et al. 1996 Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon β-1b Neurology 47 1463 1468 1:CAS:528:DyaK2sXjsFylsQ%3D%3D 8960728
14. Montalban X (2008) BENEFIT trial results. Presentation at: CONy 2nd World Congress on Controversies in Neurology; 25 October, Athens
15. D Langdon, et al. 2009 Report of cognitive difficulties by multiple sclerosis and carers: the multiple sclerosis neuropsychological questionnaire data from the CogniMS Baseline Cohort Mult Scler 15 S115
16. A Weinstein SIL Schwid RB Schiffer, et al. 1999 Neuropsychologic status in multiple sclerosis after treatment with Glatiramer Arch Neurol 56 319 324 1:STN:280:DyaK1M3gsFSqtQ%3D%3D 10.1001/archneur.56.3.319 10190822
17. SR Schwid AD Goodman A Weinstein, et al. 2007 Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial J Neurol Sci 255 57 63 10.1016/j.jns.2007.01.070 17331542 (Pubitemid 46414020)
18. RA Rudick WH Stuart PA Calabresi, et al. 2006 Natalizumab plus interferon β-1a for relapsing multiple sclerosis N Engl J Med 354 911 923 1:CAS:528:DC%2BD28XitVertLw%3D 10.1056/NEJMoa044396 16510745
19. CH Polman PW O'Connor E Havrdova, et al. 2006 A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899 910 1:CAS:528:DC%2BD28XitVertL4%3D 10.1056/NEJMoa044397 16510744
20. M Trojano F Pellegrini D Fuiani, et al. 2007 New natural history of interferon-β-treated relapsing multiple sclerosis Ann Neurol 61 300 306 1:CAS:528:DC%2BD2sXlvFChur4%3D 10.1002/ana.21102 17444502 (Pubitemid 46676729)
21. M Trojano F Pellegrini D Paolicelli, et al. 2009 Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment J Neurol Sci 286 109 113 1:CAS:528:DC%2BD1MXht1Cmur7O 10.1016/j.jns.2009.06.036 19615696
22. Y Barak A Achiron 2002 Effect of Interferon β-1b on cognitive functions in multiple sclerosis Eur Neurol 47 11 14 1:CAS:528: DC%2BD38XmtFGjtQ%3D%3D 10.1159/000047940 11803186
23. S Flechter J Vardi Y Finkelstein, et al. 2007 Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon β-1b: an open-label prospective 1 year study IMAJ 9 457 459 1:CAS:528: DC%2BD2sXot1Sgur8%3D 17642394
24. F Patti MP Amato S Bastianello, et al. 2010 Effects of immunomodulatory treatment with subcutaneous interferon β-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis Mult Scler 16 1 68 77 1:CAS:528:DC%2BC3cXislSrtbk%3D 10.1177/1352458509350309 19995846
25. Canale S, Falautano M, Martinelli et al. (2009) Cognitive and affective 24-month follow-up of multiple sclerosis patients treated with glatiramer acetate or itnerferon-β: the "Immunomodulating treatments affective and cognitive aspects" (ITACA) study. Mult Scler 15:P756